Cell adhesion molecules and extracellular matrix proteins: potential therapeutic applications

Bibliography

• MOUSA SA: Recent advances in cell adhesion mole-cules (CAM) research & development: targeting CAM for therapeutic and diagnostic applications. Drugs of The Future (1996) 21(3):283–289.
   Google Scholar
• KISHIMOTO TK, ANDERSON, DC: The role of integrins in inflammation. In: Gallin JI, Goldstein IM, Synderman R (Eds.), Raven, New York, NY, (1992):353.
   Google Scholar
• CHERESH D: Integrins: structure, function and biologi-cal properties. Adv. Mol. Cell Biol. (1993) 6:225–252.
   Google Scholar
• COX D, AOKI T, SEKI J, MOTOYAMA Y, YOSHIDA K: The pharmacology of the integrins. Merl. Res. Rev. (1994) 14 (2):195–228.
   PubMed Web of Science ®Google Scholar
• ALBELDA SM, BUCK CA: Integrins and other cell adhe-sion molecules. FASEB J. (1990) 4:2868–2880.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WM, SIELECZAK MW, AHMED A, CORTES A et a4-integrins mediate antigen-induced late bron-chial responses and prolonged airway hyperrespon-sivness in sheep. J. Clin. Invest. (1994) 93:776–782.
   PubMed Web of Science ®Google Scholar
• METZGER WJ: Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Springer Semin. Immunopathol. (1995) 16:567–478.
   Web of Science ®Google Scholar
• YEDNOCK TA, CANNON C, FRITZ LC, SANCHEZ-MADRID F, STEINMAN L, KARIN N: Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin. Nature (199) 356:63–66.
   Google Scholar
• ELICES MJ, OSBORN L, TAKADA Y et al.: VCAM-1 on acti-vated endothelium interacts with the leukocyte in-tegrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell (1990) 60:577.
   PubMed Web of Science ®Google Scholar
• BERLIN C, BERG EL, BRISKIN M J et al.: a487 integrin me-diates lymphocyte binding to the mucosal vascular ad-dressin MAdCAM-1. Cell (1993) 74:185.
   Google Scholar
• ARNAOUT MA: Structure and function of the leukocyte adhesion molecule CD11/CD18. Blood (1990) 75:1037.
   PubMed Web of Science ®Google Scholar
• ARNAOUT MA, LANIER LL, FALLER DV: Relative contribu-tion of the leukocyte molecules Mo 1, LFA-1, and p150/95 (leuM5) in adhesion of granulocytes and monocytes to vascular endothelium is tissue- and stimulus-specific. J. Cell Physiol. (1988) 137:305.
   PubMed Web of Science ®Google Scholar
• DUSTIN ML, SPRINGER TA: Lymphocyte function-associated antigenl (LFA-1) interaction with intercel-lular adhesion molecule-1 (ICAM-1) is one of at least three mechanism for lymphocyte adhesion to cul-tured endothelial cells. J. Cell Biol. (1988) 107:321.
   PubMed Web of Science ®Google Scholar
• HARLAN JM: Leukocyte adhesion deficiency syndrome: insights into the molecular basis of leukocyte emigra-tion. Clin. Immunol. Immunopath. (1993) 67:S16.
   PubMedGoogle Scholar
• ANDERSON DC, SCHMALSTEIN FC, FINEGOLD MJ et al.: The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical fea-tures. J. Inf Dis. (1985) 152:668.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E, PIERSCHBACHER M: Arg-Gly-Asp: a versa-tile cell recognition sequence. Cell (1986) 44:517–518.
   PubMed Web of Science ®Google Scholar
• PHILIPS DR, CHARO IF, SCARBOROUGH R: GPIlb/Ifia: the responsive integrin. Cell (1991) 65:359–362.
   PubMed Web of Science ®Google Scholar
• MOUSA S, BOZARTH J, FORSYTHE M et al: Antiplatelet efficacy and specificity of a novel platelet GPIlb/Ifia re-ceptor antagonist, DMP728. Cardiology (1993) 83(5–6)374–382.
   Google Scholar
• NICHOLS AJ, RUFFOLO RR, HUFFMAN WF, POSTE G, SAMANEN J: Development of GPIlb/Ifia antagonists as antithrombotic drugs. Trends Pharmacol. Sci. (1992) 13(11):413–417.
   PubMed Web of Science ®Google Scholar
• COLLER BS, FOLTS JD, SCUDDER LE, SMITH SR: Anti-thrombotic effect of a monoclonal antibody to the platelet glycoprotein Ilb/Ifia receptor in an experi-mental animal model. Blood (1986) 68:783–786.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, PLOW EF: Clinical trials of platelet receptor inhibitors. Thromb. Haemost . (1993) 70: (1):94–98.
   PubMed Web of Science ®Google Scholar
• TCHENG JE, ELLIS SG, GEORGE BS et al.: Pharmacody-namics of chimeric glycoprotein Ilb/Ifia integrin anti-platelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 90:1757–64.
   PubMed Web of Science ®Google Scholar
• MOUSA S, TOPOL E: Novel antiplatelet therapies: re-cent advances in the development of platelet GPIlb/Ifia receptor antagonists. In: Current Review of Interventional Cardiology (Third Edition). Serruys PW, Hol-mes D (Eds.), Current Medicine, Philadelphia, PA, (1997)13:114–129.
   Google Scholar
• PEERLINCK K, DE LEPELEIRE I, GOLDBERG M et al.: MK383 (L-700462), a selective nonpeptide platelet gly-coprotein Ilb/Ifia antagonist, is active in man. Circula-tion (1993) 88(4 pt 0:1512–1517.
   Google Scholar
• MOUSA S, BOZARTH J, FORSYTHE M et al.: Antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation (1994) 89:3–12.
   PubMed Web of Science ®Google Scholar
• MOUSA SA, FORSYTHE M, LORELLI W et al.: Novel non-peptide antiplatelet glycoprotein Ilb/Ifia receptor an-tagonist, DMP 754: receptor binding affinity and specificity. Coron. Artery Dis. (1996) 7:767–774.
   PubMed Web of Science ®Google Scholar
• PFAFF M, TANGEMANN K, MULLER B et al.: Selective rec-ognition of cyclic RGD peptides of NMR defined con-formation by afibb3, av03 and a581 integrins. J. Biol. Chem. (1994) 269:20233–20238
   PubMed Web of Science ®Google Scholar
• BROOKS PC, MONTGOMERY AMP, ROSENFELD M et al.: Integrin ct,03 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 749:1157–1164.
   Web of Science ®Google Scholar
• HEALY J, MURAYAMA 0, MAEDA T et al.: Peptide ligands for integrin ct,03 selected from random phage display libraries. Biochemistry (1995) 34:3948–3955.
   Google Scholar
• CHERESH D: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor in-volved in attachment to fibrinogen and von Wille-brand factor. Proc. Natl. Acad. Sci. USA (1987) 84:6471–6475.
   PubMed Web of Science ®Google Scholar
• SATO M, SARDANA M K, GRASSER WA et al.: Echistatin is a potent inhibitor of bone resorption in culture. J. Cell. Biol. (1990) 111:1713–1723.
   PubMed Web of Science ®Google Scholar
• LESSEY BA, CASTELBAUM AJ, SAWIN SW et al.: Aberrant integrin expression in endometrium of women with endometriosis. J. Clin. Endocrinol. MetaboL (1994) 79:643–649.
   PubMed Web of Science ®Google Scholar
• LUNA J, TOBE T, MOUSA S et al.: Antagonists of integrinavf33 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75:563–573.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, SANDERS L C et al: Localiza-tion of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin avI33. Cell (1996) 85:683–693.
   PubMed Web of Science ®Google Scholar
• FOXALL C, WATSON SR, DOWBENKO D et al.: The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oli-gosaccharide. J. Cell Biol. (1992) 117:895–902.
   PubMed Web of Science ®Google Scholar
• HOGG N: Roll, roll, roll your leucocyte gently down the vein. Immunol. Today (1992) 13:113–115.
   PubMedGoogle Scholar
• LEWISOHN DM, BARGATZE RF, BUTCHER EC: Leukocyte-endothelial cell recognition: evidence of a common molecular mechanism shared by neutro-phils, lymphocytes, and other leukocytes. (1987) J. Im-munol 138:4313-4319. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(3)
   Google Scholar
• MUNRO JM, LO SK, CORLESS C et al.: Expression of sialyl-Lewis X, an E-selectin ligand, in inflammation, immune processes, and lymphoid tissues. Am. J. Pa-thol. (1992) 141:1397–1408.
   PubMed Web of Science ®Google Scholar
• TEDDER TF, ISAACS CM, ERNST TJ et al.: Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Ho-mology with the mouse lymphocyte homing receptor and other human adhesion proteins. J. Exp. (1989) 170:123–128.
   Google Scholar
• GREEN PJ, TAMATANI T, WATANABE T et al.: High affin-ity binding of the leukocyte adhesion molecule Lse-lectin to 3'-sulfated-Le(a) and -Le(x) oligosaccharides and the predominance of sulfate in this interaction demonstrated by binding studies with a series of lipid-linked oligosaccharides. Biochem. Biophys. Res. Com-mun. (1992) 188:244–251.
   PubMed Web of Science ®Google Scholar
• KURZ RW, GRAF B, GREMMEL F, WURNIG C, STOCKEN-HUBER F: Increased serum concentrations of adhesion molecules after coronary angioplasty. Clin. Sci. (1994) 87:627–633.
   PubMed Web of Science ®Google Scholar
• KISHIMOTO TK, JUTILA MA, BERG EL, BUTCHER EC: Neu-trophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. (1989) Science 245:1238–1241.
   Google Scholar
• GALLATIN WM, WEISSMANN IL, BUTCHER EC: A cell-surface molecule involved in organ-specific homing of lymphocytes. (1983) Nature 304:30–33.
   Google Scholar
• JUTILA MA, WATTS G, WALCHECK B, KANSAS GS: Char-acterization of a functionally important and evolution-arily well-conserved epitope mapped to the short consensus repeats of E-selectin and L-selectin. J. Exp. Med. (1992) 175:1565–1573.
   PubMed Web of Science ®Google Scholar
• BERG EL, MAGNANI J, WARNOCK RA, ROBINSON MK, BUTCHER EC: Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). Biochem. Biophys. Res. Commun. (1992) 184:1048–1055.
   PubMed Web of Science ®Google Scholar
• SAWADA M, TAKADA A, OHWAKI I et al: Specific expres-sion of a complex sialyl Lewis X antigen on high endo-thelial venules of human lymph nodes: possible candidate for L-selectin ligand. Biochem. Biophys. Res. Commun. (1993) 193:337–347.
   PubMed Web of Science ®Google Scholar
• VON ANDRIAN UH, HANSELL P, CHAMBERS JD et al.: L-selectin function is required for beta 2-integrin-mediated neutrophil adhesion at physiological shear rates in vivo. Am. J. Physic)]. (1992) 263:H1034–H1044.
   Web of Science ®Google Scholar
• ZIMMERMAN GA, PRESCOTT SM, MCINTYRE TM: Endo-thelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today (1992) 13:93–100.
   PubMedGoogle Scholar
• LAMPETER ER, KISHIMOTO TK, ROTHLEIN R et al.: Ele-vated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes (1992) 41:1668–1671.
   PubMed Web of Science ®Google Scholar
• GEORGE JN, PICKETT EB, SAUCERMAN S et al.: Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac sur-gery. J. Clin. Invest. (1986) 78:340.
   Google Scholar
• GRUSCHWITZ M S, HORNSTEIN OP, VONDENDRIESCH P:Correlation of soluble adhesion molecules in the pe-ripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum. (1995) 38:184–189.
   PubMed Web of Science ®Google Scholar
• SAKAMAKI F, ISHIZAKA A, HANDA M et al: Soluble form of P-selectin in plasma is elevated in acute lung injury. Amer. J. Respir. Grit. Care Med. (1995) 151:1821–1826.
   PubMed Web of Science ®Google Scholar
• JOHNSTON GI, BLISS GA, NEWMAN PJ, MCEVER RP: Structure of the human gene encoding GMP-140, a member of the selectin family of adhesion receptors for leukocytes. J. Biol. Chem. (1990) 265:21381.
   PubMed Web of Science ®Google Scholar
• STENBERG PE, MCEVER RP, SHUMAN MA, JACQUES YV, BAINTON DF: A platelet alpha-granule membrane pro-tein is expressed on the plasma membrane after acti-vation. J. Cell Biol. (1985) 101:52–55.
   Web of Science ®Google Scholar
• COLLINS T L, KASSNER PD, BIERER BE, BURAKOFF SJ: Ad-hesion receptors in lymphocyte activation. Curr. Opin. Immunol (1994) 6:385–393.
   PubMed Web of Science ®Google Scholar
• DIAMOND MS, STAUTON DE, MARLIN SD, SPRINGER TA:Binding of the integrin Mac-1 (CD11b/CD18) to the immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell (1991) 65:961–971.
   PubMed Web of Science ®Google Scholar
• STAUNTON DE, DUSTIN ML, SPRINGER TA: Functionalcloning of ICAM-2, a cell adhesion ligand for LFA-1 ho-mologous to ICAM-1. Nature (1989) 339:61–64.
   PubMed Web of Science ®Google Scholar
• DE FOUGEROLLES AR, STACKER SA, SCHWARTING R, SPRINGER TA: Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J. Exp. Med. (1991)174:253–267.
   PubMed Web of Science ®Google Scholar
• GAHMBERG C G, NORTAMO P, ZIMMERMANN D, RUO-SLAHTI E: The human leukocyte-adhesion ligand, intercellular-adhesion molecule 2. Expression and characterization of the protein. Eur. J. Biochem. (1991) 177:177–182.
   Google Scholar
• SETH RR, SALCEDO M. PATARROYO, MAKGOBE MW: ICAM-2 peptides mediate lymphocyte adhesion by binding to CD11a/CD18 and CD49d/CD29 integrins. FEBS (1991) 282:193–196.
   PubMed Web of Science ®Google Scholar
• CAMPANERO MR, DEL POZO MA, ARROYO AG et al:ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway. J. Cell Biol. (1993) 123:1007–1016.
   PubMed Web of Science ®Google Scholar
• DE FOUGEROLLES AR, SPRINGER TA: Intercellular adhe-sion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J. Exp. Med. (1992) 175:185–190.
   PubMed Web of Science ®Google Scholar
• DE FOUGEROLLES AR, KLICKSTEIN LB, SPRINGER TA: Cloning and expression of intercellular adhesion molecule 3 reveals strong homology to other immuno-globulin family counter-receptors for lymphocyte function-associated antigen 1. J. Exp. Med. (1993) 177:1187–1192.
   PubMed Web of Science ®Google Scholar
• DE FOUGEROLLES AR, STACKER SA, SCHWARTING R, SPRINGER TA: Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. J. Exp. Med. (1991) 174:253–267.
   PubMed Web of Science ®Google Scholar
• DELPOZO MA, PULIDO R, MUNOZ C et al.: Regulation ofICAM-3 (CD50) membrane expression on human neu-trophils through a proteolytic shedding mechanism. Eur. j Immunol. (1994) 24:2586–2594.
   PubMed Web of Science ®Google Scholar
• DOUSSIS-ANAGNOSTOPOULOU I, KAKLAMANIS L, COR-DELL J et al.: ICAM-3 expression on endothelium in lymphoid malignancy. Am. J. Pathol. (1993) 143:1040–1043.
   PubMed Web of Science ®Google Scholar
• FAWCETT J, HOLNESS CLL, NEEDHAM LA et al: Molecularcloning of ICAM-3, a third ligand for LFA-1, constitu-tively expressed on resting leukocytes. (1992) Nature 360:481–484.
   Google Scholar
• CARLOS TM, SCHWARTZ BR, KOVACH NL et al.: Vascular cell adhesion molecule-1 mediates lymphocyte adher-ence to cytokine-activated cultured human endothe-lial cells [published erratum appears in 1990 Blood (1990) Dec 1:76(11):2420]. Blood 76:965.
   Google Scholar
• CYBULSKY MI, FRIES JW, WILLIAMS AJ et al.: Alternative splicing of human VCAM-1 in activated vascular endo-thelium. Am. J. Pathol. (1991) 138:815.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ, GORDON JL, GEARING AJ et al: (1993). The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atheroscle-rosis. J. Pathol (1993) 171:223–229.
   Web of Science ®Google Scholar
• DELISSER HM, NEWMAN PJ, ALBELDA SM: Molecular and functional aspects of PECAM-1/CD31. Immunol. Today (1994) 15.
   PubMedGoogle Scholar
• BOGEN S, PAK J, GARIFALLOU M, DENG X, MULLER WA:Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J. Exp. Merl. (1994) 179:1059–1064.
   PubMed Web of Science ®Google Scholar
• BERGER R, ALBELDA SM, BERD D et al.: Expression ofplatelet-endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. J. Cutan. Pathol. (1993) 20:399–406.
   PubMed Web of Science ®Google Scholar
• BUCK CA, BALDWIN HS, DELISSER H et al.: Cell adhesionreceptors and early mammalian heart development: an overview. Curr. Rev. Acad. Sci. (1993) 316:838–859.
   PubMed Web of Science ®Google Scholar
• DELISSER H M, NEWMAN PJ, ALBELDA SM: Platelet endo-thelial cell adhesion molecule (CD31). Curr. Top. Micro-bic)]. Immunol. (1993) 184:37–45.
   PubMedGoogle Scholar
• GEMMELL E, WALSH LJ, SAVAGE NW, SEYMOUR GJ: Ad-hesion molecule expression in chronic inflammatory periodontal disease tissue. J. Periodontal. Res. (1994) 29:46–53.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY AM, REISFELD RA, CHERESH DA: In-tegrin avf33 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc. Natl. Acad. ScL USA (1994) 91:8856–8860.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, CLARK RAF, CHERESH DA: Requirement ofvascular integrin ccv03 for angiogenesis. Science (1994) 264:569–571.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: versatility, modulation and sig-naling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• JULIANO RL, HASKILL S: Signal transduction from the extracellular matrix. J. Cell Biol. (1993) 120:577–585.
   PubMed Web of Science ®Google Scholar
• MEREDITH JE, FAZELI B, SCHWARTZ M: The extracellu-lar matrix as a cell survival factor. Mol. Biol. Cell (1993) 4:953–961.
   PubMed Web of Science ®Google Scholar